false 0001506251 0001506251 2024-12-18 2024-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) December 18, 2024

 

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-38174   27-3425913

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

11 Commerce Drive, 1st Floor, Cranford, NJ   07016
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 967-6677

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value   CTXR   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01 Other Events.

 

On December 18, 2024, Citius Pharmaceuticals, Inc. (the “Company”) received written notice of compliance from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for 12 consecutive trading days, from November 26, 2024 to December 12, 2024, the closing bid price of the Company’s common stock has been at $1.00 per share or greater, and accordingly, the Company regained compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq informed the Company in the compliance notice that it now considered this matter closed.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      CITIUS PHARMACEUTICALS, INC.
       
Date: December 20, 2024   /s/ Leonard Mazur
      Leonard Mazur
      Chairman and Chief Executive Officer

 

v3.24.4
Cover
Dec. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 18, 2024
Entity File Number 001-38174
Entity Registrant Name Citius Pharmaceuticals, Inc.
Entity Central Index Key 0001506251
Entity Tax Identification Number 27-3425913
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 11 Commerce Drive
Entity Address, Address Line Two 1st Floor
Entity Address, City or Town Cranford
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07016
City Area Code (908)
Local Phone Number 967-6677
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol CTXR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Citius Pharmaceuticals Charts.
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Citius Pharmaceuticals Charts.